Sasanka M Handunnetti, Mary Ann Anderson, Kate I Burbury, Philip A Thompson, Glenda Burke, Mathias Bressel, Juliana L Di Iulio, Rodney John Hicks, David A Westerman, Stephen Lade, Christiane Pott, Rishu Agarwal, Rachel M Koldej, David Ritchie, Martin Dreyling, Mark A Dawson, Sarah-Jane Dawson, John F Seymour, Andrew W Roberts, Constantine S Tam
In the phase-2 clinical trial (AIM) of venetoclax-ibrutinib, 24 patients with mantle cell lymphoma (MCL; 23 with relapsed/refractory [R/R] disease) received ibrutinib 560mg and venetoclax 400mg both once daily. High complete remission (CR) and measurable residual disease negative (MRD-negative) CR rates were previously reported. With median survivor follow-up now exceeding 7 years, we report long-term results. Treatment was initially continuous, with elective treatment interruption (ETI) allowed after protocol amendment for patients in MRD-negative CR...
April 25, 2024: Blood